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Primary glial tumours account for almost half of all
central nervous system tumours (Russell &
Rubinstein, 1977) with over 50% of these being the
most malignant form: glioblastoma multiforme.
While the addition of radiotherapy and
chemotherapy has extended the mean survival time
for these patients (Green et al., 1983), all current
forms of treatment are palliative and mean survival
is only 1 year. Because of the poor overall results
obtained with radiotherapy and chemotherapy in
the treatment of malignant gliomas (Schold, 1981)
and the interaction noted between these neoplasms
and the immune system (Brooks et al., 1972, 1976,
1977, 1978; Mahaley et al., 1977; Wilkstrand &
Bigner, 1980), immunotherapy has been a
frequently proposed therapeutic adjuvant. Actual
trials of immunotherapy, however, have been
limited and largely unsuccessful (Albright, 1977;
Bloom, W.H. et al., 1960; Bloom, H.J.G. et al.,
1973; Grace et al., 1961; Ommaya, 1976; Trouillas,
1973; Wikstrand & Bigner, 1980; Young et al.,
1977). In prior work, we have demonstrated that
the production of significant levels of detectable
antibodies to human glioma-associated antigens is
possible without induction of experimental allergic
encephalomyelitis (EAE) following repeated
immunization with viable tissue-cultured cells
derived from human glioblastoma multiforme tissue
in non-human primates (Bigner et al., 1981b). To
further evaluate this potentially promising mode of
preliminary therapy, a toxicity study utilizing
specific-active immunotherapy with viable, allogenic
human glioma-derived cell lines was designed.
Five patients were selected from patients
admitted to the National Hospital for Nervous
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Diseases with a putative diagnosis of malignant
glioma. For selection into the study, it was required
that the patient had undergone subtotal resection of
the tumour, exhibited a Karnofsky functional rating
>70 (Karnofsky et al., 1948), was taking no
steroids, and, because viable cells were to be used,
was immunocompetent. The criteria for immuno-
competence were: a WBC >5,000cellsmm-3 and
either a >5mmm cutaneous hypersensitivity
response (DHR); response to at least one of 3 recall
antigens: streptokinase-streptodornase (SK-SD)
(Steptokinase 100,000 units and steptodornase
25,000 units/vial) (1:10 dilution) (Lederle, London),
purified protein derivative (PPD) (middle strength)
(Evans Medical, Liverpool), and candida antigen
undiluted 100,000unitsml-1 (Bencard, Brentford)
at 48h; or to 2 of 5 antigens in the LIF assay
(Bean et al., 1983). The final criterion required for
treatment was a major HLA mismatch with the
immunizing glioma cell line.
The glioma line U251-MG (for details, see below)
and the patients were typed using 150 antisera
identifying 11 A locus, 18 B locus and 6 locus
antigens. The antisera included those used in the
7th and 8th Histocompatibility Testing Workshops
(Bodmer et al., 1978; Terasaki, 1980) as well as
local sera. The glioma line was also more
extensively tested for all the currently identified
HLA antigens using 9th Histocompatibility
Workshop antisera (Albert & Mayr, 1984). All the
tests were carried out using the standard NIH
techniques with cytofluorochromasia (Bodmer &
Bodmer, 1979).
In U251-MG only 3 out of a possible 6 HLA
antigens were identified. This may mean either that
the line is homozygous for HLA or that the
antigens were not identified. The number of
mismatches is given for each case (Table I). The
number of certain mismatches assumes that U251-
MG did in fact carry the three unidentified HLA
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Table I HLA profiles of immunotherapy patients and the immunising cell
line
Mismatchesa
with immunising
cell line
Patient/Line
Designation HLA profile Certain Possible
U251-MGb A2 B18 CW5
A.F. Al AW32 B8 B40 CW3 3 6
A.J. A2 A3 BW35 B51 CW4 1 5
M.P. Al AW31 B8 B51 N.T.C 2 6
aA maximum of 6 mismatches is possible.
bTyped with 9th International Workshop antisera.
CNot tested.
antigens and the number of possible mismatches
assumes that the line was homozygous for the
antigens shown.
The human glioma-derived cell line U251-MG
used for immunization was derived from a patient
with a malignant glioma. It was chosen from
among the 15 cell lines (Bigner et al., 1981a)
because of its expression of glial fibrallary acidic
protein (GFAP), tumorigenicity in athymic mice,
lack of induction of EAE with hyperimmunization
in non-human primates and its induction of cross
reacting glioma-associated antibodies in primates
(Bigner et al., 1981b; Wikstrand & Bigner, 1980;
Bigner et al., 1981a; Bullard et al., 1981a, 1981b).
Because the majority of prior work in primates had
been done with live cell lines with no evidence of
EAE noted, viable HLA mismatched cells were
utilized.
U251-MG cells were grown in Hams FIO media
with 20mM% HEPES and 10% FCS (Flow
Laboratories, UK). The cells were then suspended
in a BCG-cw preparation of 750mgml-1 of cell
wall material in a suspension of 0.2% Tween-80
detergent (Sigma Chemicals, Poole, UK) and 20%
mineral oil (light liquid Paraffin, B.P.C. Macarthys,
UK). The BCG and Tween solution was brought to
a final volume of 5ml with added Tween, giving a
final concentration of 750,ug of BCG-cw per ml of
solution. From this, 670pl were removed and
divided into 4 equal aliquots for a final inoculation
of 500jug BCG combined with 1-10 x 107 of live
cells.
Following surgery, all patients were also treated with
the most effective form of conventional therapy which
consisted of a combination of radiotherapy and
chemotherapy. For this protocol, radiation was
administered to the whole head in fractionated doses to a
total dose of 40-50Gy over a 4-6 week period beginning
2-4 weeks after operation. From 2-6 weeks after
completion of radiation therapy, patients began
chemotherapy. Chemotherapy consisted of vincristine
sulphate (VCR) (Oncovin, Lilly) 1.4mgm-2 i.v. as a
single dose, 1-(2-choloethyl)-3-cyclohexyl-1-nitrosourea
(CCNU) (Lundbeck, UK) 110mgm-2 as a single oral
dose and procarbazine (PCB) (Natulan, Roche) 60mgm-2
given orally each day for 10 days. This cycle was repeated
every 6 weeks so that patients received 12 cycles over an
18-20 month period. Patients were reviewed clinically and
haematologically every 6 weeks on an outpatient basis.
Karnofsky scores were recorded and FBC, electrolytes
and liver enzymes levels were routinely monitored. CT
scans were performed every 3 months during active
therapy and every 6 months following completion of
therapy.
Immunotherapy was begun one week following surgery.
Subsequent booster doses consisting of 107 tumour cells
alone were inoculated one week prior to the
chemotherapy treatments every 6 weeks. Blood samples
for serum and haematological analyses were obtained
prior to each inoculation. Disease progression was defined
as a marked deterioration in clinical status, which was
often accompanied or preceded by a worsening in the CT
scan. CT evaluation was based upon the classification
used by Levin et al. (1977), ranging from markedly better
(3+) to markedly worse (-3).
The complement-dependent cytotoxic antibody
[14C]nicotinamide release assay and the minor
variations of the assay method introduced for use
with cultured human glioma cells have been
previously described (Wikstrand et al., 1977).
Briefly, human glioma cells were seeded in each
well of Terasaki test plates in complete medium and
[14C]-nicotinamide (Amersham/Searle Corp.,
Arlington Heights, IL, USA) and allowed to reach
confluence in a 10-36h incubation at 37°C. After
removal of unincorporated label, serum dilutions
were added, followed by incubation at 37°C,
addition of rabbit complement, and supernatant
sampling to assess [14C]nicotinamide release in
comparison with maximum release controls. The
percentage of specific [14C]nicotinamide release was
determined by the formula:IMMUNOTHERAPY FOR GLIOMAS 285
testcpm-background,,pm x 100=% specific release
maxcpm-backgroundcpm
Results were then expressed as the percentage of
specific release based upon medium and
complement controls; specific release >25% was
considered significant. All serum samples were
assayed at three concentrations: undiluted, and
diluted 1/4 and 1/16, for any given sample
maximum specific release was presented.
Techniques for serum absorption have been
published (Wikstrand et al., 1977; Wikstrand &
Bigner, 1979). For the assays reported here, each
serum sample was absorbed with either pooled
human peripheral blood leucocytes (PBL) or with
cultured osteogenic sarcoma cell line 2-T cells. All
absorbed serum samples were centrifuged at
100,OOOg for I h to remove antibody-antigen
complexes prior to use in the [14C]nicotinamide
assay.
Of the 5 patients selected for the preliminary study, two
were excluded early in the trial because of either poor
tolerance ofradiotherapy or the occurrence of a pulmonary
embolus. The 3 remaining patients (Tables II and III)
received between 6-11 courses of chemotherapy and 9-17
immunotherapy courses following whole head irradiation
(Table III). The intervals from initial surgery to clinical
deterioration for these 3 patients ranged from 309 days to
729 days while total survival time ranged from 383-934
days. Two of these patients, (A.J. and A.F.) maintained
high Karnofsky levels until death (Figure 1). Patient A.F.
required a second operation for debulking of recurrent
tumour over 2 years after the initial operation. Following
the second operation, there was clinical improvement and
survival for 8 more months. Patient A.J. deteriorated 309
days following the initial surgery. Aspiration of a cyst in
the tumour bed resulted in a short clinical improvement
with demise 74 days later. The third patient, M.P.,
maintained a high Karnofsky for 18 months then
deteriorated precipitously. A reoperation for debulking of
the tumour did not result in a significant improvement in
the Karnofsky score and death occurred 6 months later.
All 3 patients receiving serial immunizations initially
demonstrated erythema and induration following local
immunizations. After the second or third immunization,
however, no evidence of local reaction was subsequently
seen.
Serial CT scans were performed in these patients. In all
3 of the patients, following surgery and irradiation there
was a significant improvement in the CT scan (Figure 1).
Initially, in one patient, A.F., only postoperative changes
were seen, while the other 2 patients maintained small
amounts of residual tumour. In patients A.F. and A.J.,
clinical deterioration was preceded -3 months by
radiographic evidence of tumour recurrence. Patient M.P.,
however, failed to show evidence of tumour recurrence
despite significant clinical deterioration. The CT findings
correlated generally with the findings at autopsy.
Table II Patient profile
Patient Age Sex Operation Tumor Location Histology
MP 36 Male Lobectomy +Cyst Bifrontal Anaplastic
Aspiration Gemistocytic
Astrocytoma
AJ 64 Female Subtotal Resection L Parietal Glioblastoma
+Cyst Aspiration Multiforme
AF 33 Female Lobectomy L Temporal Glioblastoma
Multiforme
Table III Clinical progress ofpatients
Relapsefreec
X-raya Chemotherapyb Immunotherapy intervals Survival
Patient treatment courses courses (days) (days)
MP Yes 9 15 534 872
AJ Yes 6 9 309 383
AF Yes 11 17 729 934
a40( OGy of whole head irradiation.
bProcarbazine (60mgm 2), CCNU-1-(2-Chloroethyl)-3-Cyclohexyl-1-
Nitrosourea (75mgm 2), Vincristine (1.4mgm-2), given at intervals of 6
weeks.
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Figure 1 Serologic and clinical profile of 3 patients receiving serial immunotherapy: (a) Patient A.F., (b)
Patient A.J. and (c) Patient M.P. Upper panel % specific [14C]-nicotinamide release assay against the immunizing cell line U-251 MG. Centre panel: Serial CT scans on a scale of 3+; marked improvement through; -3, marked deterioration. Lower panel: Clinical status by Karnofsky scale compared to time following original surgery and in relationship to immunotherapy (m) and chemotherapy (U) treatments.
(4) = death.
The 3 patients who received satisfactory immuno-
therapy courses all underwent second operations at 10-25
months following the initial procedure (Table IV). In none
of the surgical or autopsy examinations was there any
evidence of an allergic encephalomyelitis despite specific
attention to this possible development.
All 3 patients developed varying degrees of anaemia
and leukopenia during their therapy. Patient A.F. required
three transfusions in temporal association with
chemotherapy. During this same time period and white
count ranged from 13,100 to 1,800 with a progressive
decline during the first 10 months of therapy stabilizing at
between 5,000 and 2,200. Platelet counts during this time
period ranged between 381,000 and 53,000, the degree of
thrombocytopenia roughly correlating with the degree of
leucopenia. On 5 occasions, the white count was measured
at the time of immunization and 1 week subsequently. On
4 of those 5 occasions, a 5-44% decrease in total white
count was noted 1 week following immunization. The
second patient, A.J., maintained a haemoglobin between
10.4-14.4 during the first 12 months of therapy. During
this time period, the white count was between 2,800 and
4,800 and the platelet count from 61,000 to 363,000.
Twelve months following surgery, after receiving the 8th
immunization, the patient's haemoglobin dropped from
11.3 to 5.8 over 5 days. The white count ranged from
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Table IV Pathological changes
Patient First Operation Second Operation Autopsy
MP Anaplastic Gemistocytic Astrocytoma Residual Tumour
Astrocytoma Radiation Changes
AJ Glioblastoma Multiforme Glioblastoma Residual Glioma
Multiforme
AF Glioblastoma Multiforme Astrocytoma Residual Tumour
1,300 to 2,000 and the platelet count was from 50,000 to
79,000. At this time, the patient developed a generalized
rash and the Westergren sedimentation rate, which had
ranged from 11 to 33 rose to between 43 and 163. The
patient was admitted to hospital for an evaluation of the
anaemia and possible sepsis. Multiple cultures including
sputum, blood, cerebrospinal fluid, urine and marrow
were all negative. A sample of bone marrow demonstrated
a generalized depression compatible with cytotoxic drugs.
The patient's anaemia spontaneously cleared and the
haemoglobin was stabilized at 11.1-11.6 with white counts
from 2,600-3,400 and platelet counts from 61,000-
130,000. The Westergren sedimentation rate continued,
however, to be elevated at 92-108. The patient expired
within one month with evidence of herniation. The third
patient, M.P., maintained a haemoglobin of 11.7-15.2, a
white count of 3,300-6,800, a platelet count of 85,000-
290,000 and sedimentation rates of 6-20 during the entire
course of therapy.
Of the 3 patients receiving immunotherapy, two,
A.F. and M.P., produced levels of cytotoxic
antibody against the immunizing cell line U251-MG
(Figure 1). The 3rd patient (A.J.) produced only
negligible levels of antibody as detected by
[14C]nicotinamide release assay throughout the
course of the immunotherapy. As shown in Figure
1, the responses of patients A.F. and M.P. were
quite similar, peaking between the 5th and 6th
immunizations, followed by an abrupt and
irreversible fall in detectable complement-dependent
cytolytic antibody. In both cases, the observed drop
in cytolytic activity followed the 4th course of
chemotherapy.
The antibody titres of both patients at the peak
of their respective responses were low (Figure 2).
The 50% specific release endpoint of unabsorbed
serum was 1/32 for patient A.F. and - 1/100 for
patient M.P. Because of low antibody titre, serial
absorption to completeness as performed by
Mahaley et al. (1983) was not done; instead, either
two absorptions with pooled human PBL
(2x 107cells) or a single absorption with 107 2-T
sarcoma cells of peak response sera from patients
A.F. and M.P. were performed. Either absorbent
removed . 50% of the cyto!ytic activity of both of
these sera (Figure 2), indicating that although a
significant cytolytic antibody response was detected,
100 A.F. M.P.
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Figure 2 Antibody titres of patients (a) A.F. and (b)
M.P. at the peak of their respective serologic responses
in a ['4C]-nicotinamide release assay against
immunizing cell line U-251 MG. The 50% specific
release end-point of unabsorbed serum was 1/32 for
patient A.F. and - 1/100 for patient M.P. (0)
unabsorbed; (0) PBL-absorbed; (El) sarcoma 2T-
absorbed
the predominant cytolytic activity was not specific
for the immunogen.
In our small series of patients, a high degree of
selection was employed. This was done in order to
minimize the potential for possible tumour growth
of the viable immunizing cell line and to maximize
the potential for response. Of the 3 patients that
were serially immunized, the 2 younger patients
demonstrated an early serologic response to the
immunizing cell line. As demonstrated in previous
studies immunizing non-human primates (Wikstrand
& Bigner, 1977; Wikstrand et al., 1979), the bulk of
the antibody response to cultured glioma cells was
directed against non-immunogen specific antigens
such as; HLA-antigens, FCS-adsorbed specificities
and other nonspecific antigens with a small, but
detectable, amount of reactivity to immunogen
remaining following absorption with non-glioma
human cell absorbents; normal brain, PBL, and
control non-glioma cultured tumour cells. This is in
contrast to the results seen by Bloom et al. (1973)
utilizing autologous irradiated glioma cells.
However, in that study only 10/27 patients received
multiple inoculations and no patients received
adjuvant. In contrast, Trouillas & Lapras (1969)
found identifiable immunodiffusion precipitation288 D.E.. BULLARD et al.
reactions with autologous tumour extracts in 14/20
patients whom they immunized serially with
autologous tumour tissue mixed with Freund's
complete adjuvant. In subsequent work from that
same group, positive DHR reactions were seen in
23/24 patients to glioma cell lines following
immunization (Febvre et al., 1972). Whether the
selection of potentially immunocompetent patients
plays a role in this response to therapy remains
more speculative than the use of adjuvant. Other
than the serologic response of these 2 patients and
the local reactions, there was no evidence that a
significant immunologic reaction occurred. In none
of the 3 patients was there any leukocytosis,
development of increased reaction to glioma
extracts on LIF assay or an increase in lymphocytic
infiltration of their tumours at autopsy or second
surgical procedure. But because all 3 patients
underwent cytotoxic chemotherapy during this
period of time, it is hard to clearly assess the
interaction between these two phenomena.
It may be speculated that the prolonged survival
seen in the 2 patients who mounted serologic
responses is related to the immunotherapy.
However, these patients were young and had high
initial Karnofsky scores, both of which influence
the natural history of the disease. A similar finding
of prolonged survival has been reported from a
separate study using irradiated cells from this same
immunizing cell line in combination with BCG-cw,
Levamisole and chemotherapy with BCNU
(Mahaley et al., 1983). In that study, 20 patients
with malignant gliomas were selected for active
immunization with either U251-MG cell line or
D54-MG cell line, both of which were derived from
malignant gliomas. Patients who were inoculated
with the U251-MG cell line had a longer survival
time when compared to those inoculated with D54-
MG cell line or when compared with historical
controls treated with Levamisole, radiation therapy
and chemotherapy. Differences in titre between
viable versus irradiated cells were not significantly
different when both were used in non-human
primates (Wikstrand & Bigner, 1981). This appears
to also be true in humans, although only limited
data exist on this point. Although no toxicity was
seen in this study utilizing live cells, the lack of
definite advantage and the potential for
complications would suggest that future studies
should display irradiated cells. While no definitive
conclusions can be drawn from these 2 small series,
further clinical and immunologic evaluation of
active immunotherapy would appear to be
warranted.
The question of haematologic compromise is also
suggested from the data obtained in these patients.
However, comparative haematologic data from 126
patients receiving similar chemotherapy were
essentially identical. Patients undergoing immuno-
therapy were also subject to phlebotomy twice as
often as chemotherapy patients, which may have
played a significant role in their haematologic
compromise. This, in association with the use of
cytotoxic drugs, may explain this phenomenon.
Why 2 of the 3 patients also developed episodes of
anaemia in association with elevated sedimentation
rates is unexplained despite extensive evaluation.
No evidence of infection was seen and only
generalized bone marrow depression compatible
with chemotherapy was noted. At autopsy, neither
of these patients demonstrated any evidence of
allergic encephalomyelitis or a significant auto-
immune reaction.
In summary, *adjuvant therapy of malignant
gliomas with viable, HLA mismatched glioma cells
appears to be a safe form of therapy that deserves
further evaluation because of its theoretical
potential. In this study, two of three patients
receiving immunotherapy had prolonged survival
and evidence of a serologic response to the
immunizing cell line. No evidence of local tumour
growth or an allergic encephalitis was seen.
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